Simon Fietz
Bonn, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.
Journal: Frontiers in immunology
Published: November 22, 2023
Manifestation of subacute cutaneous lupus erythematosus during treatment with anti-PD-1 antibody cemiplimab - a case report.
Journal: Frontiers in immunology
Published: October 19, 2023
Circulating Cell-Free SHOX2 DNA Methylation Is a Predictive, Prognostic, and Monitoring Biomarker in Adjuvant and Palliative Anti-PD-1-Treated Melanoma.
Journal: Clinical chemistry
Published: July 26, 2023
CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma.
Journal: Pigment cell & melanoma research
Published: July 25, 2023
CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma.
Journal: Clinical epigenetics
Published: December 20, 2022
DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy.
Journal: Clinical epigenetics
Published: December 18, 2021
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab).
Journal: Cancer immunology, immunotherapy : CII
Published: July 23, 2020
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.
Journal: EBioMedicine
Published: February 19, 2020
Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.
Journal: Cancer immunology, immunotherapy : CII
Published: January 24, 2019
Showing 1-10 of 10
Last Updated: 09/26/2026